Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

IDL Biotech: Q2 Review

2020-07-23

16:41

LS

Ludvig Svensson

Redeye gives its comment on IDL’s Q2 report. As estimated in our previous research note, the quarter saw a significant sales drop owing to down-priorities in the healthcare systems with the corona crisis. IDL guides for a better third quarter and we find it reasonable that FY 2020 sales could reach our forecasted SEK ~30 million, which would represent only a slight decrease in sales compared to last year’s figures. In this note, we share our impressions of the report, as well as our view on CEO Charlotte Berg’s resignation.

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers